By mapping microbial-metabolic niches, CMS identifies patients likely to benefit from HDAC inhibition combined with microbiome remodeling [e.g., fecal microbiota transplantation (FMT)], addressing a critical unmet need in CRC precision oncology. The gene discussed is HDAC9; the disease is colorectal carcinoma.